1-(4-methoxyphenyl)-3-(6-quinoxalinyl)thiourea is a chemical compound with the molecular formula C17H14N4OS. It is a thiourea derivative, meaning it contains a thiourea functional group (NH2-CS-NH2).
The compound's structure includes a 4-methoxyphenyl ring and a 6-quinoxalinyl ring connected by the thiourea group. This specific arrangement of functional groups and aromatic rings contributes to its potential biological activity.
**Importance in Research:**
The specific importance of this compound for research depends on the context and application. However, thiourea derivatives are known to exhibit a wide range of biological activities, including:
* **Antimicrobial activity:** Thioureas are known to inhibit the growth of bacteria, fungi, and viruses. This compound might be investigated for its potential as an antimicrobial agent, particularly against specific pathogens.
* **Antioxidant activity:** Some thioureas have shown antioxidant properties, protecting cells from damage caused by free radicals. This could make 1-(4-methoxyphenyl)-3-(6-quinoxalinyl)thiourea relevant for research into oxidative stress and its role in various diseases.
* **Anticancer activity:** Thiourea derivatives have been studied for their anticancer potential, particularly against leukemia and solid tumors. This specific compound may be investigated for its ability to inhibit cancer cell growth and proliferation.
* **Enzyme inhibition:** Thioureas can act as inhibitors of certain enzymes, potentially impacting metabolic processes and disease development. This compound may be explored for its potential to modulate specific enzyme activities.
**Further Research:**
To determine the specific importance of 1-(4-methoxyphenyl)-3-(6-quinoxalinyl)thiourea, further research is required. This may involve:
* **Biological activity assays:** Testing the compound against various pathogens, cell lines, and enzymes to assess its potential efficacy.
* **Mechanism of action studies:** Investigating how the compound interacts with biological targets and exerts its effects.
* **Pharmacokinetic and toxicological studies:** Assessing the compound's absorption, distribution, metabolism, and excretion in the body, as well as its potential toxicity.
Overall, 1-(4-methoxyphenyl)-3-(6-quinoxalinyl)thiourea represents a promising candidate for research into various biological activities and its potential for therapeutic applications. However, further investigation is needed to fully understand its specific properties and its potential role in medicine or other fields.
ID Source | ID |
---|---|
PubMed CID | 972779 |
CHEMBL ID | 1427219 |
CHEBI ID | 114745 |
Synonym |
---|
n-(4-methoxyphenyl)-n'-6-quinoxalinylthiourea |
smr000200258 |
MLS000581626 , |
zinc00613132 , |
CHEBI:114745 |
1-(4-methoxyphenyl)-3-quinoxalin-6-ylthiourea |
HMS2551L10 |
1-(4-methoxyphenyl)-3-(6-quinoxalinyl)thiourea |
bdbm34735 |
cid_972779 |
1-(4-methoxyphenyl)-3-quinoxalin-6-yl-thiourea |
CHEMBL1427219 |
Q27196151 |
sr-01000280981 |
SR-01000280981-1 |
SDCCGSBI-0137243.P001 |
Class | Description |
---|---|
quinoxaline derivative | Any naphthyridine derivative that is a derivative of quinoxaline (1,4-naphthyridine). |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 3.9716 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 7.9433 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 39.8107 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 26.8545 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 44.6684 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 14.5810 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 14.3979 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 12.5893 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 31.6228 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 25.1189 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
67.9K protein | Vaccinia virus | Potency | 31.6228 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 19.9526 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 65.8114 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
snurportin-1 | Homo sapiens (human) | Potency | 65.8114 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 11.2202 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 75.6863 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 26.6514 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
MPI protein | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.1900 | 13.8256 | 50.1000 | AID1220 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
signal transducer and activator of transcription 1-alpha/beta isoform alpha | Homo sapiens (human) | EC50 (µMol) | 13.3200 | 0.4180 | 1.3618 | 2.9980 | AID1397 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |